GARY BLACKBURN, President
Dr. Gary Blackburn is a seasoned executive with successes in both the pharma and diagnostics business sectors. He currently serves as President and Director for Islet Sciences, Inc. He focuses on advising early-stage biotech firms in operational infrastructure, business development, and the effective protection of intellectual property, serving as CEO of BioMeDx Advisors, a consulting firm he established in 2010. Prior to that, he served as Chief Executive Officer and Director of Claremont BioSolutions from 2010 through 2015, bringing to market the SimplePrep® x8 system for automated DNA sample preparation for molecular diagnostics. Dr. Blackburn served as President and CEO of Ohmx Corporation, developing a protein diagnostics platform, from 2005 to 2010. Prior to his tenure at Ohmx, Dr. Blackburn served as Director of Research at Motorola Life Sciences and VP of Research & Technology at Clinical Micro Sensors (acquired by Motorola for $300 million in 2001). For two years, Dr. Blackburn served on the Motorola M&A team that first sold the CodeLink® microarray platform and assets to Amersham Biosciences in 2004 and then in 2005 spun-out Clinical Micro Sensors from Motorola, merging it with a second company to form GenMark Molecular Diagnostics. Prior to that, he served as Director of Technology Management at Boehringer Mannheim/Roche Pharmaceuticals, tasked with identifying and acquiring access to pharmaceutical and diagnostic technologies that would be key to next-generation product lines. Among other accomplishments, he was responsible for licensing the LightCycler® technology into Roche from BioFire (now bioMerieux, formerly Idaho Technologies). Early in Dr. Blackburn’s career he led the research team and developed the IP portfolio at IGEN International, forming an alliance with Boehringer Mannheim (acquired by Roche Diagnostics) which eventually led to a $1.8 billion acquisition of the company by Roche. Dr. Blackburn earned a B.S. degree in Chemistry as well both an M.S. and Ph.D. in Bioengineering from the University of Utah. He also fulfilled an NSF postdoctoral fellowship at Cornell University.
JOHN STEEL, Director of Business Development
Mr. Steel has held leadership positions in numerous biotechnology companies. Most recently, Mr. Steel was the founder and chairman of Islet Sciences, Inc. The company is publicly traded and develops DMA-based diagnostics, small molecules for diabetes and related disorders and an artificial pancreas. Mr. Steel is a contributor to numerous global healthcare patents. Mr. Steel is a graduate of Dartmouth College and earned an MBA from USC.
Medical & Scientific Advisors
THOMAS J. KINDT, Ph.D
Dr. Kindt, has previously served as Chief Scientific Officer of Diomics Corp., of San Diego and InNexus Biotechnology. For the past 11 years, Dr. Kindt has served as an adjunct member of the Department of Biology at the University of New Mexico and authored a major textbook on immunology. From 1995 to 2005, Dr. Kindt served as Director, Division of Intramural Research, NIAID, NIH, in Bethesda, Maryland. There he was responsible for the management of the Division including 1,300 staff members, as well as overseeing an annual budget of $340 Million, and research facilities in Bethesda, Rockville and Frederick, Maryland; Hamilton, Montana; Bamako, Mali, and Rakai District, Uganda. Dr. Kindt holds a Bachelor of Science in Chemistry (cum laude) from Thomas More College and Ph.D., in BioChemistry from the University of Illinois at Urbana–Champaign.
CHRISTIAN MENDE, M.D.
Clinical Professor of Medicine at University of California, San Diego Fellow of the American College of Physicians, the American Society of Hypertension, Nutrition and Nephrology
KEVAN HEROLD, M.D.
Professor of Immunology and Medicine at Yale University